Clinical Trial Update: Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 study of AMG 655 with mFOLFOX6 and bevacizumab in first-line metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• AMG 655 (AMG-655)
• Bevacizumab (bevacizumab)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Amgen | Conditions: Metastatic Colorectal Cancer, Colon Cancer | Phase 1, Phase 2 | Status: COMPLETED